atorvastatin has been researched along with Neoplasms in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (28.57) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 12 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JS; Kim, Y; Lee, J | 1 |
| Kiełbik, A; Kulbacka, J; Novickij, V; Rembiałkowska, N; Saczko, J; Szewczyk, A; Szlasa, W; Tarek, M; Łapińska, Z | 1 |
| Abolghasemi, R; Ai, J; Ebrahimi-Barough, S; Mohamadnia, A | 1 |
| Chen, D; Gao, Y; Hu, H; Jia, L; Qiao, M; Song, Z; Tang, Y; Wang, C; Zhao, X | 1 |
| Irie, N; Oltvai, ZN; Sugiura, A; Tashiro, J; Warita, K; Warita, T; Zhou, Y | 1 |
| Alvandi, M; Dehbanpour, MR; Farzipour, S; Nosrati, S; Shaghaghi, Z | 1 |
| Liu, L; Qin, X; Ran, L; Sun, Q; Tang, C; Wang, Y; Xiao, J; Xu, X; Zhang, G | 1 |
| Patrono, C; Pedicino, D | 1 |
| Oh, TK; Song, IA | 1 |
| Hassanabad, AF | 1 |
| Rao, PS; Rao, US | 1 |
| Hosaka, YZ; Ishikawa, T; Ohta, KI; Oltvai, ZN; Shimakura, H; Sugiura, A; Tashiro, J; Warita, K; Warita, T | 1 |
| Marlatt, KL; Sadak, KT | 1 |
| Batista, ML; Bedard, AH; Birbrair, A; Bueno, LL; Correa, VA; Farmer, SR; Franco, FO; Guilherme, A; Henriques, F; Knobl, P; Lopes, MA; Peres, SB; Santos, KB | 1 |
| Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG | 1 |
| Cunnane, G; Durcan, L; Gleeson, N; McKiernan, S | 1 |
| Chotenimitkhun, R; D'Agostino, R; Hamilton, CA; Herrington, DM; Hundley, WG; Jordan, JH; Lash, TL; Lawrence, JA; Vasu, S; Yeboah, J | 1 |
| Xiao, H; Yang, CS | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 2 |
| Choi, Y; Kim, DE; Lee, DK; Park, JE; Schellingerhout, D; Shon, SM | 1 |
| Ghalali, A; Högberg, J; Stenius, U; Ye, ZW | 1 |
| Cao, J; Fan, L; Gao, Y; Liu, XF; Lu, XC; Yang, HY | 1 |
| Ravnskov, U | 1 |
| Mascitelli, L; Pezzetta, F | 1 |
| Goldstein, MR | 1 |
| Kapoor, S | 1 |
| Dimitroulakos, J; Minden, MD; Penn, LZ; Tan, MM; Wong, WW; Xia, Z | 1 |
3 review(s) available for atorvastatin and Neoplasms
| Article | Year |
|---|---|
A review of effects of atorvastatin in cancer therapy.
Topics: Adjuvants, Immunologic; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunotherapy; Neoplasms; Radiation Oncology | 2022 |
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment | 2019 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
1 trial(s) available for atorvastatin and Neoplasms
| Article | Year |
|---|---|
Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Neoplasms; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2015 |
24 other study(ies) available for atorvastatin and Neoplasms
| Article | Year |
|---|---|
Atorvastatin-mediated rescue of cancer-related cognitive changes in combined anticancer therapies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Cell Proliferation; Cognitive Dysfunction; Computational Biology; Cytokines; Humans; Models, Biological; Neoplasms; Neoplastic Stem Cells; Signal Transduction; Trastuzumab; Tumor Cells, Cultured | 2021 |
Atorvastatin Modulates the Efficacy of Electroporation and Calcium Electrochemotherapy.
Topics: Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Atorvastatin; Calcium; Cell Membrane; Cell Membrane Permeability; Cell Proliferation; Cholesterol; Electrochemotherapy; Electroporation; Humans; Neoplasms; Tumor Cells, Cultured | 2021 |
Synergistic inhibitory effect of human umbilical cord matrix mesenchymal stem cells-conditioned medium and atorvastatin on MCF7 cancer cells viability and migration.
Topics: Atorvastatin; Cell Proliferation; Culture Media, Conditioned; Humans; Mesenchymal Stem Cells; Neoplasms; Umbilical Cord | 2022 |
Self-amplified ROS production from fatty acid oxidation enhanced tumor immunotherapy by atorvastatin/PD-L1 siRNA lipopeptide nanoplexes.
Topics: AMP-Activated Protein Kinases; Atorvastatin; B7-H1 Antigen; Humans; Immunotherapy; Lipopeptides; Neoplasms; Reactive Oxygen Species; RNA, Small Interfering; Tumor Microenvironment | 2022 |
Alterations in the omics profiles in mevalonate pathway-inhibited cancer cells.
Topics: Atorvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Neoplasms; Polyamines; Purines | 2023 |
pH-Responsive Selenium Nanoplatform for Highly Efficient Cancer Starvation Therapy by Atorvastatin Delivery.
Topics: Atorvastatin; Humans; Hydrogen-Ion Concentration; Neoplasms; Selenium; Tumor Microenvironment | 2023 |
Adverse effects of anthracyclines: does atorvastatin STOP-CArdiotoxicity?
Topics: Anthracyclines; Antibiotics, Antineoplastic; Atorvastatin; Cardiotoxicity; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms | 2023 |
Drug-specific and dosage effects of statins and the risk of cancer: a population-based cohort study in South Korea.
Topics: Adult; Atorvastatin; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Retrospective Studies | 2021 |
Is There a Role for Statins and Metformin in Cancer Therapy?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kallikreins; Male; Metformin; Neoplasms; PC-3 Cells; Prostate-Specific Antigen | 2020 |
Statins decrease the expression of c-Myc protein in cancer cell lines.
Topics: Atorvastatin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Neoplasms; Proto-Oncogene Proteins c-myc; Simvastatin | 2021 |
Concomitant attenuation of HMGCR expression and activity enhances the growth inhibitory effect of atorvastatin on TGF-β-treated epithelial cancer cells.
Topics: Atorvastatin; Biomarkers, Tumor; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Size; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl CoA Reductases; Models, Biological; Neoplasms; RNA, Messenger; Transforming Growth Factor beta | 2021 |
Re: "The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial" by Marlatt et al. (J Adolesc Young Adult Oncol. 2017 [Epub ahead of print]; DOI: 10.108
Topics: Atorvastatin; Child; Humans; Neoadjuvant Therapy; Neoplasms; Survivors | 2018 |
Toll-Like Receptor-4 Disruption Suppresses Adipose Tissue Remodeling and Increases Survival in Cancer Cachexia Syndrome.
Topics: 3T3-L1 Cells; Adipose Tissue; Adiposity; Animals; Atorvastatin; Cachexia; Carcinoma, Lewis Lung; Disease Models, Animal; Gene Deletion; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Survival Analysis; Syndrome; Toll-Like Receptor 4; Tumor Cells, Cultured | 2018 |
A benign tumor as the apparent trigger for myopathy.
Topics: Aged; Atorvastatin; Female; Gynecologic Surgical Procedures; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Leg; Leiomyoma; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Neoplasms; Pyrroles; Treatment Outcome; Uterine Neoplasms | 2014 |
The TNT study, women and cancer.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Estrogens; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Neoplasms; Pyrroles; T-Lymphocytes, Regulatory | 2009 |
Atorvastatin and clopidogrel interfere with photosensitization in vitro.
Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cathepsin B; Cell Line; Clopidogrel; Heptanoic Acids; Humans; Light; Macrophages; Mice; Neoplasms; Photochemotherapy; Photosensitizing Agents; Polyethylene Glycols; Polylysine; Porphyrins; Pyrroles; Ticlopidine | 2011 |
Silencing p110β prevents rapid depletion of nuclear pAkt.
Topics: Animals; Atorvastatin; Cell Line, Tumor; Cell Nucleus; Class I Phosphatidylinositol 3-Kinases; Fibroblasts; Gene Silencing; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Knockout; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; RNA, Small Interfering; Tacrolimus Binding Proteins | 2011 |
The molecular mechanism of the anticancer effect of atorvastatin: DNA microarray and bioinformatic analyses.
Topics: Antineoplastic Agents; Atorvastatin; Cell Cycle; Cell Line; Computational Biology; Endothelial Cells; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrroles | 2012 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Neoplasms; Pyrroles | 2003 |
Statin treatment, reduced T-cell content of atherosclerotic plaques and cancer.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Heptanoic Acids; Humans; Immunity, Cellular; Neoplasms; Pyrroles; T-Lymphocytes | 2006 |
Analyzing the results of the treating to new targets study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Neoplasms; Pyrroles | 2008 |
Statins, leptin and regulatory T cells.
Topics: Animals; Atorvastatin; Heptanoic Acids; Humans; Leptin; Lymphocyte Activation; Neoplasms; Obesity; Pyrroles; Risk Factors; T-Lymphocytes, Regulatory; Thinness | 2008 |
Atorvastatin and celecoxib: a future role in cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Pyrazoles; Pyrroles; Sulfonamides | 2008 |
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.
Topics: Acute Disease; Apoptosis; Atorvastatin; Cell Division; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia, Myeloid; Lovastatin; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Pyrroles; Sensitivity and Specificity; Tumor Cells, Cultured | 2001 |